Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. reports developments in its biopharmaceutical royalty aggregation and technology-licensing business. The company partners with pharmaceutical and biotechnology companies, funds late-stage clinical development programs in exchange for long-term economic interests, and manages royalty interests across development- and commercial-stage therapeutic assets.
Recurring LGND news includes operating and financial results, royalty revenue drivers, material agreements, capital-structure updates, and partner clinical or regulatory events tied to products in the portfolio. Company updates also cover proprietary technologies such as Captisol® and NITRICIL™, business-development activity, and portfolio assets such as FILSPARI® where Ligand has an economic interest.
Ligand Pharmaceuticals (Nasdaq: LGND) announced plans to offer $400 million of convertible senior notes due 2030 in a private placement to qualified institutional buyers. The company will also grant initial purchasers a 13-day option to buy up to $60 million in additional notes.
The notes will be senior unsecured obligations with semiannual interest payments starting April 1, 2026. Upon conversion, Ligand will pay cash up to the principal amount and may settle the remainder in cash, stock, or a combination. The company plans to use the proceeds for convertible note hedge transactions, up to $30 million for share repurchases, and general corporate purposes including potential business investments.
To manage dilution, Ligand will enter into convertible note hedge and warrant transactions with option counterparties, though the warrant transactions could have a dilutive effect if the stock price exceeds the warrant strike price.
Ligand Pharmaceuticals (Nasdaq: LGND) reported strong Q2 2025 financial results and raised its full-year guidance. Total revenue reached $47.6 million, up 15% year-over-year, driven by a 57% increase in royalty revenue to $36.4 million. The company raised its 2025 guidance, now expecting total revenue of $200-225 million and adjusted EPS of $6.70-7.00.
Key highlights include the completion of the Pelthos Therapeutics merger, a $40 million strategic investment in Orchestra BioMed, and the commercial launch of Zelsuvmi. The company maintains a strong financial position with $245 million in cash and investments, including $26.5 million in Viking Therapeutics stock.
Ligand Pharmaceuticals (NASDAQ:LGND) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host a conference call and webcast at 8:30 AM ET to discuss the quarterly performance and provide a business update.
Investors can access the call via phone at (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (International) using Conference ID 3661098. A live webcast and replay will also be available through the company's website.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™, the first FDA-approved at-home treatment for molluscum contagiosum. The launch triggered a $5 million milestone payment to Ligand.
Following Pelthos' merger with Channel Therapeutics, Ligand now owns 56% of Pelthos. The agreement includes a 13% royalty on worldwide ZELSUVMI sales and potential for additional $5 million in commercial sales milestones.
Ligand Pharmaceuticals (Nasdaq: LGND) has completed its merger between subsidiary LNHC, Inc. and Channel Therapeutics' subsidiary CHRO Merger Sub Inc. The combined entity, Pelthos Therapeutics, will trade on NYSE American under ticker "PTHS" starting July 2, 2025.
Concurrent with the merger, Pelthos raised $50.1 million in equity capital, with $32 million from the Murchinson-led investor group and $18 million from Ligand. The company is preparing to launch ZELSUVMI™, an FDA-designated novel drug for Molluscum contagiosum infections, in July 2025. Ligand will receive a 13% royalty on worldwide ZELSUVMI sales.
ZELSUVMI is the first home-administered prescription treatment for molluscum, a condition affecting an estimated 16.7 million people in the US. Pelthos will also evaluate Channel's NaV 1.7 programs for various pain treatments.
Ligand Pharmaceuticals (LGND) has announced it will ring The Nasdaq Stock Market Opening Bell on Monday, May 19, 2025. CEO Todd Davis, along with senior management and board members, will participate in the ceremony to celebrate recent company milestones, including two value-creating transactions.
Davis highlighted Ligand's transformation into a profitable, infrastructure-light organization that focuses on acquiring and generating royalties from a diverse biopharmaceutical product portfolio. The company aims to continue building on its two-year momentum, supporting partner development of breakthrough medicines, and creating long-term shareholder value. The ceremony will be broadcast live at 9:15 a.m. Eastern Time.
Ligand Pharmaceuticals (Nasdaq: LGND) has announced its senior management team's participation in three upcoming investor conferences in May 2025:
- H.C. Wainwright Royalty Company Conference (Virtual) - Fireside chat on May 13 at 3:30 p.m. ET
- RBC Capital Markets Global Healthcare Conference (New York) - Fireside chat on May 20 at 2:05 p.m. ET
- Craig-Hallum Institutional Investor Conference (Minneapolis) - One-on-one meetings on May 28
Management will be available for one-on-one meetings with investors during all conferences. Interested investors should contact their respective conference representatives to arrange meetings.
Ligand Pharmaceuticals (Nasdaq: LGND) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
The conference call will be accessible via phone at (800) 715-9871 for U.S. & Canada callers and (646) 307-1963 for international participants, using Conference ID 3661098. A live webcast and replay of the call will also be available.